Vnitr Lek 2017, 63(5):307-310 | DOI: 10.36290/vnl.2017.063

A present view on ivabradine in the therapy of cardiovascular diseases

Jiří Slíva
Ústav farmakologie 3. LF UK, Praha

Cardiovascular illnesses belong to diseases with the highest prevalence. They are also the most predominant reason of death in the vast majority of European countries. Hence, the offer of effective treatment of these dis-eases is absolutely crucial. This text focuses on the current therapeutical use of ivabradine in its approved indications - chronic stable angina pectoris and chronic heart failure - in the context of so far published relevant clinical trials.

Keywords: angina pectoris; bradines; heart failure; If current; ischemic heart disease; ivabradine

Received: March 6, 2017; Accepted: March 24, 2017; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. A present view on ivabradine in the therapy of cardiovascular diseases. Vnitr Lek. 2017;63(5):307-310. doi: 10.36290/vnl.2017.063.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kannel WB, Kannel C, Paffenbarger RS Jr et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113(6): 1489-1494. Go to original source... Go to PubMed...
    2. Seccareccia F, Pannozzo F, Dima F et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001; 91(8): 1258-1263. Go to original source... Go to PubMed...
    3. Palatini P. Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms. Drugs 2007; 67(Suppl 2): S3-S13. Go to original source... Go to PubMed...
    4. Diaz A, Bourassa MG, Guertin MC et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26(10): 967-974. Go to original source... Go to PubMed...
    5. Tavazzi L. Heart rate as a therapeutic target in heart failure? Eur Heart J Suppl 2003; 5(Suppl G): G15-G18. Go to original source...
    6. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103(10): 1428-1433. Go to original source... Go to PubMed...
    7. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9641): 807-816. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(08)61170-8>. Go to original source... Go to PubMed...
    8. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372(9641): 817-821. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(08)61171-X>. Go to original source... Go to PubMed...
    9. Koster R, Kaehler J, Meinertz T. [REDUCTION Study Group]. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J 2009; 158(4): e51-e57. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2009.06.008>. Go to original source... Go to PubMed...
    10. Tardif JC, Ponikowski P, Kahan T. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol. 2013; 168(2): 789-794. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2012.10.011>. Go to original source... Go to PubMed...
    11. Werdan K, Ebelt H, Nuding S et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol 2012; 101(5): 365-373. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392-011-0402-4> Go to original source... Go to PubMed...
    12. Fox K, Ford I, Steg PG et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371(12): 1091-1099. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1406430>. Go to original source... Go to PubMed...
    13. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875-885. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(10)61198-1>. Go to original source... Go to PubMed...
    14. Volterrani M, Cice G, Caminiti G et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011; 151(2): 218-224. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2011.06.098>. Go to original source... Go to PubMed...
    15. Fox K, Komajda M, Ford I et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34(29): 2263-2270. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht101>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.